Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Transplantation. 2016 Nov;100(11):2453–2460. doi: 10.1097/TP.0000000000001025

Table 5.

Associations between HLA zygosity and diffuse large B-cell lymphoma

Antigen Zygosity Transplant recipients with DLBCL Transplant recipients without DLBCL SIR IRRa 95% CI P value

n (%) n (%)
A Heterozygous 771 (85.48) 146,613 (85.57) 12.06 1.00 reference
Homozygous 130 (14.41) 24,526 (14.32) 12.04 0.95 (0.75–1.18) 0.6363
B Heterozygous 822 (91.13) 156,972 (91.62) 11.99 1.00 reference
Homozygous 79 (8.76) 14,161 (8.27) 12.83 1.09 (0.82–1.43) 0.5365
C Heterozygous 277 (30.71) 61,742 (36.04) 11.12 1.00 reference
Homozygous 270 (29.93) 47,970 (28.00) 12.06 1.00 (0.82–1.23) 0.9708
DQ Heterozygous 519 (57.54) 106,082 (61.92) 11.34 1.00 reference
Homozygous 217 (24.06) 39,244 (22.91) 12.07 0.99 (0.81–1.19) 0.8915
DR Heterozygous 759 (84.15) 146,386 (85.44) 11.93 1.00 reference
Homozygous 133 (14.75) 24,285 (14.17) 12.31 0.99 (0.79–1.24) 0.9541

DLBCL=Diffuse large B-cell lymphoma; SIR=Standardized incidence ratio; IRR=Incidence rate ratio

a

IRRs were calculated as the ratio of incidence rates between homozygous versus heterozygous (reference) antigen carriers, and were adjusted for sex, age at transplant, race/ethnicity, year of transplant, transplanted organ, and transplant number.